Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Halobetasol Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 0.78 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.78 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | USP2 | O75604 | 2/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.75 |
| ▸ | MLNR | O43193 | 1/20 | 0.75 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.75 |
| ▸ | PPARG | P37231 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Halobetasol Propionate SCHEMBL6006526 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL2849994 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL14518060 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL6753214 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL13321839 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL10905947 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL17190306 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL10905949 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL2849995 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL14339615 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10854 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710918-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE | Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) | 2026-03-18 | — | — | EP | claimed |
| US-20250152705-A1 | COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-05-15 | — | — | US | claimed |
| WO-2025090570-A1 | ANTI-OX40L ANTIBODIES AND METHODS OF USE | ABCELLERA BIOLOGICS INC. (CA) | 2025-05-01 | — | — | WO | claimed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | claimed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| US-20250099498-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2025-03-27 | — | — | US | claimed |
| EP-3943073-B1 | BIODEGRADABLE POLYMER MICROPARTICLE CONTAINING STEROID-BASED DRUG AND PREPARATION METHOD THEREFOR | REGENBIOTECH INC (KR) | 2025-03-26 | — | — | EP | claimed |
| WO-2025054169-A1 | COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2025-03-13 | — | — | WO | claimed |
| US-20250082572-A1 | TOPICAL FORMULATIONS FOR HANDLING ATOPIC DERMATITIS | GOLD FEET LTD. (IL) | 2025-03-13 | — | — | US | claimed |
| CN-118271385-B | Refining method of crude halobetasol propionate | 湖南玉新药业有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2000038617-A2 | COMPOSITIONS AND METHODS OF USING THE SAME | FOUR STAR PARTNERS (US) | 2000-07-06 | — | — | WO | claimed |
| CN-1253563-A | Nitrate esters of corticoid compounds and their pharmaceutical use | NICOX SA (FR) | 2000-05-17 | — | — | CN | claimed |
| US-5972920-A | TREATMENT OF PSORIASIS, ECZEMA, LICHENPLANUS, AND SEBORRHEIC DERMATITIS (DANDRUFF) | DERMALOGIX PARTNERS, INC. (US) | 1999-10-26 | — | — | US | claimed |
| EP-0929565-A2 | NITRATE ESTERS OF CORTICOID COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | NICOX S.A. (FR) | 1999-07-21 | — | — | EP | claimed |
| WO-1998015568-A2 | NITRATE ESTERS OF CORTICOID COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | NICOX S.A. (FR) | 1998-04-16 | — | — | WO | claimed |
| EP-0675722-A1 | HYDROXY VITAMIN D3 COMPOUNDS FOR TREATING SKIN ATROPHY | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1995-10-11 | — | — | EP | claimed |
| WO-1994014453-A1 | HYDROXY VITAMIN D3 COMPOUNDS FOR TREATING SKIN ATROPHY | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1994-07-07 | — | — | WO | claimed |
| US-5326566-A | As solvents, water or oil soluble surfactants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-07-05 | — | — | US | claimed |
| EP-0513832-A1 | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products | Bristol-Myers Squibb Company (US) | 1992-11-19 | — | — | EP | claimed |
| US-4619921-A | Polyhalogeno-steroids | CIBA-GEIGY CORPORATION (US) | 1986-10-28 | — | — | US | claimed |